The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.

The tool uses two blood-based biomarkers and up to five clinical features to generate a risk score for prostate cancer aggressiveness.

Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space are optimistic of continued growth.

The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.

The agreement includes $650 million of 4.35 percent senior notes, $500 million of 4.55 percent senior notes, and $850 million of 4.8 percent senior notes.